Literature DB >> 29185849

RAS ubiquitylation modulates effector interactions.

Ryan Thurman1, Edhriz Siraliev-Perez1, Sharon L Campbell1,2.   

Abstract

RAS proteins function as molecular switches that regulate cellular growth by cycling between active GTP- and inactive GDP bound states. While RAS activity is modulated by factors (guanine nucleotide exchange and GTPase activating proteins) that control levels of active Ras-GTP, RAS proteins also undergo a number of post-translational modifications that regulate their function. One such modification is ubiquitylation. Monoubiquitylation of KRAS at lysine 147 (mUbRAS) enhances Ras activation and promotes signaling through the RAF and Phosphoinositide 3-Kinase (PI3K) signaling pathways. We have previously shown that mUbRAS leads to activation of RAS through a defect in GTPase activating protein (GAP) mediated downregulation, similar to the action of most oncogenic mutations. Consistent with these findings, we now show that mUbRASimpairsRAS binding to the p120 GAP catalytic domain. Mutations in activated G12V RAS that prevent ubiquitylaton at 147 show a decrease in tumorigenesis, suggesting that in addition to activating KRAS, monoubiquitylation at this site may promote downstream signaling and transformation. To investigate whether mUbRAS alters RAS effector interactions, we chemically ubiquitylated KRAS at residue 147 and characterized binding of mUbRAS to RAS binding domains (RBDs) from three distinct downstream effectors that play key roles in RAS-mediated transformation. Results from these studies show a decrease in binding of mUbRAS (7-10-fold) relative to the CRAF RAS Binding Domain (RBD), the catalytic subunit of Phosphoinositide 3-Kinase catalytic gamma (PI3Kcγ) and RALGDS RBD. Intriguingly, we find that mUbRAS shows greatly enhanced (> 40-fold) binding to the CRAF RBD when bound to GDP. These findings, taken together, suggest that mUbRASmay promoteactivation of RAS through a GAP defect, and facilitate RAF association and MAPK signaling in a nucleotide independent manner.

Entities:  

Keywords:  RAS GTPase; allostery; effector; signal transduction; ubiquitylation

Mesh:

Substances:

Year:  2017        PMID: 29185849      PMCID: PMC7549706          DOI: 10.1080/21541248.2017.1371267

Source DB:  PubMed          Journal:  Small GTPases        ISSN: 2154-1248


  29 in total

1.  Mutational and kinetic analyses of the GTPase-activating protein (GAP)-p21 interaction: the C-terminal domain of GAP is not sufficient for full activity.

Authors:  P Gideon; J John; M Frech; A Lautwein; R Clark; J E Scheffler; A Wittinghofer
Journal:  Mol Cell Biol       Date:  1992-05       Impact factor: 4.272

Review 2.  GTPase-activating proteins: helping hands to complement an active site.

Authors:  K Scheffzek; M R Ahmadian; A Wittinghofer
Journal:  Trends Biochem Sci       Date:  1998-07       Impact factor: 13.807

3.  Ubiquitin manipulation by an E2 conjugating enzyme using a novel covalent intermediate.

Authors:  Nadine Merkley; Kathryn R Barber; Gary S Shaw
Journal:  J Biol Chem       Date:  2005-07-12       Impact factor: 5.157

Review 4.  Regulating the regulator: post-translational modification of RAS.

Authors:  Ian M Ahearn; Kevin Haigis; Dafna Bar-Sagi; Mark R Philips
Journal:  Nat Rev Mol Cell Biol       Date:  2011-12-22       Impact factor: 94.444

5.  Quantitative structure-activity analysis correlating Ras/Raf interaction in vitro to Raf activation in vivo.

Authors:  C Block; R Janknecht; C Herrmann; N Nassar; A Wittinghofer
Journal:  Nat Struct Biol       Date:  1996-03

Review 6.  Ubiquitin-binding domains.

Authors:  James H Hurley; Sangho Lee; Gali Prag
Journal:  Biochem J       Date:  2006-11-01       Impact factor: 3.857

7.  Improved binding of raf to Ras.GDP is correlated with biological activity.

Authors:  Christina Kiel; Daniel Filchtinski; Michael Spoerner; Gideon Schreiber; Hans Robert Kalbitzer; Christian Herrmann
Journal:  J Biol Chem       Date:  2009-09-23       Impact factor: 5.157

8.  HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS.

Authors:  Moon Hee Yang; Gaelle Laurent; Alexandra S Bause; Robert Spang; Natalie German; Marcia C Haigis; Kevin M Haigis
Journal:  Mol Cancer Res       Date:  2013-05-30       Impact factor: 5.852

9.  Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma.

Authors:  M E Pacold; S Suire; O Perisic; S Lara-Gonzalez; C T Davis; E H Walker; P T Hawkins; L Stephens; J F Eccleston; R L Williams
Journal:  Cell       Date:  2000-12-08       Impact factor: 41.582

10.  The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions.

Authors:  Hossein Nakhaeizadeh; Ehsan Amin; Saeideh Nakhaei-Rad; Radovan Dvorsky; Mohammad Reza Ahmadian
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

View more
  5 in total

Review 1.  Inhibition of Nonfunctional Ras.

Authors:  Ruth Nussinov; Hyunbum Jang; Attila Gursoy; Ozlem Keskin; Vadim Gaponenko
Journal:  Cell Chem Biol       Date:  2021-01-12       Impact factor: 8.116

2.  Ubiquitylation by Rab40b/Cul5 regulates Rap2 localization and activity during cell migration.

Authors:  Emily D Duncan; Ke-Jun Han; Margaret A Trout; Rytis Prekeris
Journal:  J Cell Biol       Date:  2022-03-16       Impact factor: 8.077

3.  Monoubiquitination of KRAS at Lysine104 and Lysine147 Modulates Its Dynamics and Interaction with Partner Proteins.

Authors:  Vinay V Nair; Guowei Yin; Jerry Zhang; John F Hancock; Sharon L Campbell; Alemayehu A Gorfe
Journal:  J Phys Chem B       Date:  2021-04-30       Impact factor: 2.991

4.  A comprehensive analysis of RAS-effector interactions reveals interaction hotspots and new binding partners.

Authors:  Soheila Rezaei Adariani; Neda S Kazemein Jasemi; Farhad Bazgir; Christoph Wittich; Ehsan Amin; Claus A M Seidel; Radovan Dvorsky; Mohammad R Ahmadian
Journal:  J Biol Chem       Date:  2021-04-27       Impact factor: 5.157

Review 5.  Divergent Mechanisms Activating RAS and Small GTPases Through Post-translational Modification.

Authors:  Natsuki Osaka; Yoshihisa Hirota; Doshun Ito; Yoshiki Ikeda; Ryo Kamata; Yuki Fujii; Venkat R Chirasani; Sharon L Campbell; Koh Takeuchi; Toshiya Senda; Atsuo T Sasaki
Journal:  Front Mol Biosci       Date:  2021-07-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.